Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

THUMZUP MEDIA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Thumzup Media Corporation - TZUP

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merge...

What regulatory or legal risks could arise from the investigation by Kahn Swick & Foti, and how might those risks influence market sentiment toward TZUP? How will the share exchange ratio (Dogehash shareholders receiving 30.7 million TZUP shares) dilute existing shareholders and impact earnings per share? What are the details and timeline of the merger approval process, and how might delays affect TZUP's share price?
Symbol: TZUP
Mergers
22 days ago
Read more businesswire

Post Harvest Technologies, Inc. Launches King City Cooling, LLC to Strengthen Fresh Produce Infrastructure in California's Salad Bowl

KING CITY, Calif., Aug. 21, 2025 /PRNewswire/ -- Post Harvest Technologies, Inc., today announced the official launch of King City Cooling, LLC, a state-of-the-art cold storage and cross-dock facil...

How might this expansion influence Post Harvest's market share relative to other fresh produce infrastructure providers in California? What is the expected cost structure and ROI timeline for the new cold storage facility? How will the launch of King City Cooling affect Post Harvest Technologies' revenue forecasts?
Symbol: PHYT
Expansion
22 days ago
Read more prnewswire

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB...

Will the updated development plan require additional financing, and what are the potential dilution or partnership implications for shareholders? How does the inhaled KB707 platform compare to existing IL‑2/IL‑12 immunotherapies and other NSCLC treatments in terms of efficacy, safety, and market potential? What is the anticipated timeline and regulatory pathway for the inhaled KB707 Phase 2/3 trials in NSCLC, and how might that affect near‑term valuation?
Symbol: KRYS
Clinical trials
22 days ago
Read more globenewswire